Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 3763 3783
This examiner grants 53% of resolved cases
Nathan R. Price is an examiner in Tech Center 3700 and Art Unit 3763, where he has 517 resolved cases. His allowance rate is 53.4%, and the median days to allowance is 1484. These metrics suggest that while over half of the applications are eventually granted, the process typically involves an extended timeline. Practitioners should account for this 1484-day timeline when managing the 517 cases in this examiner's portfolio.
The data reveals an interview lift of 38.9%. This significant lift indicates that conducting an interview is a highly effective tactic for increasing the 53.4% baseline allowance rate. Given the 1484-day median pendency, the 38.9% lift offers a clear path for practitioners to improve their chances of success and potentially shorten the prosecution cycle. In Art Unit 3763, leveraging the 38.9% lift can be a key factor in navigating the 517 resolved cases and achieving a favorable outcome.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18187371 | ELONGATED CATHETER ASSEMBLY HAVING GUIDEWIRE DEFLECTOR | Non-Final OA | Boston Scientific Medical Device Limited |
| 18930330 | USER PHYSIOLOGICAL RESPONSE PREDICTION AND MANAGEMENT SYSTEMS | Non-Final OA | ABBOTT DIABETES CARE INC. |
| 18089335 | SUPRACHOROIDAL INJECTION DEVICE | Non-Final OA | Genentech, Inc. |
| 18034788 | Injector device for arrhythmia classification using measurement of cardiac activity and power analysis | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18389636 | EXPANDABLE SHEATH AND METHODS OF USING THE SAME | Non-Final OA | EDWARDS LIFESCIENCES CORPORATION |
| 18531307 | EXPANDABLE SHEATH FOR INTRODUCING AN ENDOVASCULAR DELIVERY DEVICE INTO A BODY | Final Rejection | EDWARDS LIFESCIENCES CORPORATION |
| 17937245 | LOW FLOW SWITCH FOR MEDICAL ASPIRATION | Non-Final OA | Medtronic, Inc. |
| 18030427 | INTRATUMORAL AND SYSTEMIC IMMUNIZATION USING FRACTIONAL DAMAGE-CREATING DEVICE WITH CHECKPOINT MOLECULES FOR CANCER THERAPY | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 18132575 | Blood Culture Sample Collection Device with Optimized Distal Fluid Path and Pre-Positioned and Sterilized Discard Sample Vacuum Tube | Non-Final OA | Becton, Dickinson and Company |
| 17839785 | Drug Delivery Device | Non-Final OA | SANOFI |
| 18339978 | CATHETERS FOR EMERGENCY ENDOVASCULAR SURGERY AND ASSOCIATED DEVICES, SYSTEMS, AND METHODS | Non-Final OA | University of Washington |
| 18256109 | INFUSION PUMP WITH OCCLUSION DETECTION | Final Rejection | ICU Medical, Inc. |
| 17806847 | INTRAVENOUS INFUSION PUMPS WITH SYSTEM AND PHARMACODYNAMIC MODEL ADJUSTMENT FOR DISPLAY AND OPERATION | Non-Final OA | ICU Medical, Inc. |
| 17839647 | METHOD FOR MODIFICATION OF MAXIMUM DELIVERY LIMITS IN AUTOMATIC DRUG DELIVERY SYSTEMS | Final Rejection | INSULET CORPORATION |
| 17839645 | HYBRID INJECTION-PUMP INSULIN DELIVERY | Final Rejection | INSULET CORPORATION |
| 17991399 | DEVICE AND METHOD FOR IMAGE-BASED SUPPORT OF A USER | Final Rejection | Erbe Elektromedizin GmbH |
| 17967831 | COMPOSITION FOR PROMOTING ANGIOGENESIS USING LIQUID TYPE PLASMA AND METHOD FOR PROMOTING ANGIOGENESIS USING SAME | Non-Final OA | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18309239 | ADHESIVE MEDICAL PATCH PORT | Non-Final OA | BAXTER HEALTHCARE SA |
| 17984838 | PERITONEAL DIALYSIS PRESSURE SENSING SYSTEMS AND METHODS FOR AIR DETECTION AND ULTRAFILTRATION MANAGEMENT | Final Rejection | BAXTER HEALTHCARE SA |
| 18034066 | PATCH-TYPE DRUG INFUSION DEVICE | Final Rejection | MEDTRUM TECHNOLOGIES INC. |
| 17785410 | HIGH RELIABILITY DRUG INFUSION DEVICE | Non-Final OA | MEDTRUM TECHNOLOGIES INC. |
| 17923293 | METHODS AND DEVICES FOR TREATMENT OF NEUROPATHY | Final Rejection | University of Maine System Board of Trustees |
| 18224498 | PURGE SYRINGE | Non-Final OA | CardiacAssist, Inc. |
| 17784994 | FLUID DELIVERY APPARATUS WITH MICRONEEDLES | Final Rejection | SOFUSA HOLDINGS LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy